華大基因(300676.SZ):NUPCO繼續追加3817.6萬美元的合同金額
格隆匯 5 月 10日丨華大基因(300676.SZ)公佈,截至公吿披露日,公司已累計收到NUPCO支付的上述合同款項金額為283,121,061美元。近日,公司收到NUPCO的書面通知,NUPCO基於項目執行的實際情況,需增加新冠病毒檢測綜合解決方案相關的採購,繼續追加3817.6076萬美元的合同金額,目前,雙方已簽署相關書面協議。
此次追加合同金額生效後,NUPCO於2021年度兩次追加的合同金額累計為120,976,641美元,佔公司2020年度經審計營業收入的9.28%(根據截至2021年5月10日銀行間外匯市場人民幣匯率中間價6.4425計算)。該重大合同的履行預計將對公司2021年度經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.